Legal entity

Pomerantz LLP

Company

The clearest coverage concentration is corporate-law: 10 of 11 stories, with the rest divided among 1 other category. The 99-day window averages about 0.8 stories each week. The busiest single day carried 4. Against the same-window beat baseline of 44% negative, this entity's 27% share is less negative.

Last mentioned: Aug 1, 2026

Entity pulse

Recent coverage · Pomerantz LLP

11 stories
5.3 avg impact
0% positive
27% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 27 percentage points.

  • 73% neutral
  • 27% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Pomerantz LLP

The clearest coverage concentration is corporate-law: 10 of 11 stories, with the rest divided among 1 other category. The 99-day window averages about 0.8 stories each week. The busiest single day carried 4. Against the same-window beat baseline of 44% negative, this entity's 27% share is less negative. The 5.3 average consequence score is below the beat benchmark of 6.5 in the same window. They are less corroborated than the beat average, carrying 3 original sources each against 3.1 for the same window. Pomerantz LLP is most often covered alongside Alani Nutrition, which appears in 1 of these 11 stories. Pomerantz LLP appears in 11 tracked Legal stories published from March 9, 2026 through June 15, 2026.

Stories tracked
11
Per week
0.8
Negative
27%
Sources per story
3

Computed from the 11 stories linked to this entity, with beat comparisons drawn from all 869 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Pomerantz LLP. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Discovery Phase

    Expected commencement of the discovery process if the cases survive initial motions to dismiss.

  2. Pomerantz LLP Announces Investigations

    Pomerantz issues press releases for all five companies, seeking lead plaintiffs for potential securities class actions.

  3. Celsius Texas AG Investigation

    Texas AG Paxton announces investigation into Celsius's marketing of high-caffeine drinks to children. Stock falls 7.53%.

  4. Compass Antitrust Probe Disclosure

    Media reports NY AG antitrust investigation into Compass's $1.6B acquisition of Anywhere Real Estate. Stock falls 11.82%.

  5. Wise Money Laundering Report

    The Bureau of Investigative Journalism reports Belgian probe into Wise accounts used for money laundering. Stock falls 4.63% on June 2.

  6. Photronics Q2 Earnings Miss

    Photronics reports Q2 revenue of $209M, down YoY, and operating margin contraction. Stock falls 36.4%.

  7. Gap Inc. Q1 Earnings Miss

    Gap reports Q1 revenue of $3.5B, 1% growth YoY, missing estimates; cuts full-year guidance. Stock falls 15.4% on May 29.

  8. Verra Mobility contract termination disclosure

    Received Avis Budget Group termination notice effective Sep 2026; revised 2026 outlook downward; cost cuts planned. Stock crashed 70.57% to $3.85 on May 27.

  9. Lead Plaintiff Deadline

    Estimated deadline for shareholders to petition the court to lead the litigation.

  10. Lead Plaintiff Deadline

    Final date for investors to apply for lead plaintiff status in the litigation.

  11. GeneDx Q1 2026 results

    Adjusted gross margin 74%→69%, FY revenue guide cut to $475–$490M from $540–$555M, and $31.3M impairment on Fabric Genomics. Stock drop implied.

  12. Badger Meter Q1 2026 results

    EPS of $0.93 missed by $0.26, revenue of $202.03M missed by $28.58M; utility water sales -10% YoY. Stock fell 24.13% to $115.54.

  13. Lead Plaintiff Deadline (Est)

    Anticipated deadline for shareholders to move the court for lead plaintiff appointment.

  14. Secondary Notice

    Pomerantz reinforces the filing highlights to ensure broad investor awareness.

  15. Snowflake Filing

    Pomerantz LLP issues formal notice of class action filing against Snowflake Inc.

  16. Legal Alerts

    Pomerantz LLP issues shareholder alerts for Driven Brands, CWH, and Apollo.

  17. Enphase Suit Filed

    Pomerantz LLP files class action litigation against Enphase Energy in federal court.

  18. Legal Reminders Issued

    Pomerantz LLP issues formal reminders to shareholders of MREO and RR regarding active litigation.

  19. Initial Legal Notice

    Pomerantz LLP issues the first public call for shareholders to join the class action.

  20. Pomerantz LLP Action

    Pomerantz LLP formally advises shareholders of the class action filing.

Stories mentioning Pomerantz LLP 11

Corporate Law Neutral

Pomerantz LLP Targets Mereo BioPharma and Richtech Robotics in Class Actions

Pomerantz LLP has issued formal reminders regarding class action lawsuits filed against Mereo BioPharma and Richtech Robotics, signaling a surge in securities litigation within the biotech and automation sectors. These legal actions focus on alleged violations of federal securities laws, specifically regarding material misstatements that impacted investor valuations.

2 sources

Source: pr-inside.com · pr-inside.com

Corporate Law Neutral

Pomerantz LLP Targets monday.com and Trip.com in Dual Securities Class Actions

Pomerantz LLP has initiated securities class action proceedings against SaaS leader monday.com and global travel platform Trip.com, alleging violations of federal securities laws. The firm is currently advising shareholders on lead plaintiff deadlines following claims of misleading corporate disclosures that impacted market valuations.

3 sources

Source: pr-inside.com · pr-inside.com

Pomerantz LLP is linked from 11 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.